PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 6875190

Autonomic dysfunction in clinical disorders with particular reference to catecholamine release.

R H Johnson
View original source ↗Export metadata ↓

Abstract

The role of autonomic dysfunctions in clinical disorders is discussed. Particular attention is paid to catecholamine release, plasma levels and noradrenaline clearance in various disease states and how they are affected by aging. What can be determined from plasma norepinephrine levels requires caution for reasons given. The topics dealt with most specifically are: (1) clinical dysfunctions with raised plasma catecholamine levels and how pathophysiological states may cause or be affected thereby; (2) the abnormalities produced by reduced sympathetic activity; (3) other neurological disorders affecting autonomic functions; and (4) disorders in which abnormal autonomic system function is in doubt, such as orthostatic hypotension in the elderly.

Explore related subjects

Adrenal Gland NeoplasmsAutonomic Nervous SystemAutonomic Nervous System DiseasesCatecholaminesCerebrovascular DisordersEpinephrineHeartHumansHypertensionHypotension, OrthostaticNorepinephrinePheochromocytomaPolyradiculoneuropathyReceptors, CholinergicShy-Drager SyndromeSympathetic Nervous SystemJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

R H Johnson. Autonomic dysfunction in clinical disorders with particular reference to catecholamine release.. https://doi.org/10.1016/0165-1838(83)90075-9

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2008

Treatment of neuroblastoma-related opsoclonus-myoclonus-ataxia syndrome with high-dose dexamethasone pulses.

Opsoclonus-myoclonus-ataxia-syndrome (OMS) represents a rare neuroblastoma-associated paraneoplastic syndrome that commonly results in neurologic deficits despite tumor resection and immunosuppressive therapy. We describe the response of five such children to high-dose dexamethasone pulses including two patients in whom previous glucocorticoids, rituximab, and cytostatic drugs were not successful. All patients had MYCN non-amplified tumors that were detected 1 to 7 months after the onset of the OMS or ataxia. This treatment resulted in a good partial response in three and in complete remission in two patients. Our results show that dexamethasone pulses are likely to be useful for both, first-line- and salvage-therapy for OMS-patients.

Adrenal Gland Neoplasms↗
PubMed2007

Malignant paragangliomas associated with mutations in the succinate dehydrogenase D gene.

INTRODUCTION: Malignant paragangliomas have been well described in carriers of mutations of the succinate dehydrogenase B (SDHB) gene, but have rarely been associated with mutations in the succinate dehydrogenase D (SDHD) gene. AIM: The aim of the study was to report the different clinical expression patterns of malignant paragangliomas in five patients with SDHD (D92Y) mutations observed in approximately 200 SDHD (D92Y) mutation carriers followed in our institution. RESULTS: Metastasis and/or local tumor invasion was documented 0 (n=2), 1, 18, and 30 yr after the initial diagnosis of paraganglioma. Malignancy was proven by paraganglioma bone metastases (n=2), intrathoracic paraganglioma with lymph node metastases, locally invasive head-and-neck paraganglioma with destruction of the petrosal bone, and locally invasive paraganglioma of the bladder with lymph node metastases. Four of the five patients developed catecholamine excess during follow-up due to intraadrenal paraganglioma (pheochromocytoma) (n=1), extra adrenal paraganglioma (n=2), and presumed subclinical disease (n=1). CONCLUSION: SDHD mutations (D92Y) are associated with malignant paragangliomas and catecholamine excess with remarkable interindividual variations despite the same mutation. We estimate that the prevalence of malignancy in carriers of D92Y mutations is at least 2.5%.

Adrenal Gland Neoplasms↗